From the CMS document “Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price
Applicability Year 2027“:

On January 17, 2025, CMS announced the selection of the below list of 15 drugs covered under Medicare Part D for the second cycle of negotiations (initial price applicability year 2027), based on total gross covered prescription drug costs under Medicare Part D and other criteria as required by the law.

With the Trump inauguration to take place on Monday, will the Medicare Drug Price Negotiation process change with the new administration? Anna Kaltenboeck notes in EndPoints News:

…the next administration will not have “blanket authority to change the core parts of the law,” certain aspects of the process can be changed without legislative action.

For example, CMS could alter its guidance or how it interprets parts of the law, such as how many times it meets with drugmakers, or how many listening sessions it holds. “The degree to which they play hardball with manufacturers in the process could change,” she said.